A Cohort Study of Melanoma in Patients with Dysplastic Nevi  by Halpern, Allan C. et al.
A Cohort Study of Melanoma in Patients with
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A historical cohort of 153 patients with dysplastic nevi was studied for the development of melanoma. Each subject
had a minimum follow-up of 5 years, with an average study follow-up of 94 months. Eleven new melanomas developed
in 11 patients between 11 and 143 months (average 61 months) into the study period. Age-adjusted melanoma
incidence in the cohort was 692/100,000 person years. Development of melanoma was strongly correlated with prior
personal and/ or family history of melanoma. Even among the 89 patients with no personal or family history of
melanoma, the age-adjusted incidence of melanoma was an alarming 154/100,000 person years. Within this small, non-
randomly ascertained cohort no association could be discerned between melanoma incidence and total number of
banal or dysplastic nevi. These findings support the public health significance of the recognition of dysplastic nevi
and confirm the importance of family history in evaluating melanoma risk associated with dysplastic nevi. J Invest
Dermatol 100:346S–349S, 1993
The characterization of the clinical and pathologic attributes of
dysplastic nevi by Clark et al allowed the recognition of dysplastic
nevi as markers of melanoma risk [1]. Dysplastic nevi occur in
two major epidemio-logic contexts. In hereditary melanoma/
dysplastic nevus kindreds (Kraemer’s D-2 families) [2], the
presence of a single dysplastic nevus is a sensitive phenotypic
marker of a strong genetic tendency to develop melanoma [3].
Outside the context of familial melanoma, dysplastic nevi have
been shown in six retrospective case-control studies to be
independent markers of a moderately increased melanoma risk
[4–9].
The present study used a historical cohort design to evaluate
the development of melanoma in 153 patients with dysplastic
nevi followed in the Pigmented Lesion Clinic of the University of
Pennsylvania. The findings confirm many observations and
conclusions of past retrospective studies of dysplastic nevi as
markers of melanoma risk. The dramatic rise in melanoma
incidence worldwide, coupled with the clustering of melanoma
risk factors in this identifiable segment of the population, confers
great public health significance on the recognition of dysplastic
nevi.
METHODS
The study population consisted of a group of 153 patients of the
Pigmented Lesion Clinic of the University of Pennsylvania who were
identified for a study of the natural history of individual dysplastic
nevi. All study subjects were seen for follow-up visits by our group
between February 12, 1990, and January 21, 1991. Study inclusion
criteria were a clinical and/or histologic diagnosis of me-lanocytic
dysplasia, a minimum of 5 years of prospective follow-up by our
group, and the availability of high-quality overview and close-up
photographs from the time of initial evaluation. All consenting,
eligible participants underwent personal interview to confirm and
supplement data abstracted from their charts with regard to personal
and family history of melanoma, hair color at age 20 years, tendency
to sunburn, history of sunburn, and ability to tan.
Each study subject underwent complete cutaneous examination
by any one of three authors (AH, DG, DE). Total number of normal
nevi greater than 2mm and dysplastic nevi (defined as nevi greater
than 5mm with a macular component and having variegate
pigmentation and/or irregular, fuzzy border) were recorded cate-
gorically. Categories of normal nevi were 0–15, 16–30, 31–50,
51–100, and greater than 100. Dysplastic nevi were categorized as
1–2, 3–5, 6–10, 11–20, and greater than 20. Freckling of the upper
back was assessed as absent, mild, moderate, or severe.
All melanomas prospectively diagnosed in the study population
during the study interval were identified by interview and chart
review. The medical records were reviewed and abstracted for the
date of excision, precipitant of excision, clinical diagnosis at time of
excision, and histologic attributes of each melanoma.
All demographic data except age (e.g., personal or family history
of melanoma) are reported as of the time of each patient’s final
evaluation. Subjects are assigned D-2 status based on family history
of two or more blood relatives with melanoma inclusive of the
patient’s personal history of melanoma when applicable. Incident
melanomas were included in assigning D-2 status.
Analysis Comparisons of clinical and demographic data between
studied and eligible but not studied subjects were performed using
chi-square and Student t tests. Statistical comparison of clinical and
demographic subsets among study subjects were performed using a
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chi-square statistic. Annual melanoma incidence rates were derived
by dividing the number of melanomas occurring in a given subset of
the study population by the total number of person years of follow-
up for all members of that subset. Incidence rates were age adjusted
to the 1985 Pennsylvania white population [10] using the direct
method and expressed per 100,000 patient years [11]. In this
approach, the weighted average of the crude age-specific incidence
rates is calculated using the number of people within each age group
in the standard population as weights.
RESULTS
Of 195 patients selected for study by chart review, 28 (14%) did
not keep their scheduled appointment. One hundred fifty-three
(92%) of the remaining 167 patients consented to and partici-
pated in the study. The studied group (n¼153) did not differ
significantly from the selected but unstudied group (n¼42) by
age, gender, personal history of melanoma, or number of close-up
photographs performed at initial evaluation.
The age of study subjects at entry ranged from 12.2 to 73.2
years, with an average age of 40.7 years. Seventy-five (49%) of
the subjects were male. Length of follow-up from initial
photography to final exam (‘‘study interval’’) ranged from 60 to
155 months, with a mean duration of 94 months. Hair color, eye
color, sun sensitivity, and freckling characteristics of the study
population are shown in Table I.
Fifty-four (35%) of the studied subjects had a personal history
of melanoma at study completion. Twenty-three (15%) of the
participants were members of families with two or more blood
relatives with melanoma (inclusive of affected study subjects).
Eighty-nine subjects (58%) had neither a personal history of
melanoma nor a family history of two or more blood relatives
with melanoma.
As depicted in Fig 1, counts of dysplastic nevi were highly
correlated with counts of total nevi. Fig 2 displays the relationship
between counts of dysplastic nevi and age in the study
population. After correction for age, no significant difference in
nevus counts was seen between subjects with and without a
personal or family history of melanoma.
Eleven new melanomas developed in 11 of the 153 subjects
during the study period. Characteristics of these subjects and their
melanomas are presented in Table II. The mean age of patients
developing melanoma was 44 years (range 36–51 years). The time
from baseline evaluation to diagnosis of melanoma ranged from
11 to 143 months, with an average interval of 61 months. Two of
the melanomas were in situ lesions. The remaining nine
melanomas ranged from 0.25 to 0.85mm in thickness, with a
mean thickness of 0.51mm. Of these nine, six had vertical growth
phase present. Seven of the patients developing melanoma had a
prior personal history of melanoma. Four of the melanomas
occurred in subjects with a family history of melanoma in one or
more first-degree relatives. Two of the melanomas occurred in
subjects with no personal or family history of melanoma.
Development of melanoma was strongly associated with personal
history of melanoma (po0.001) or family history of two or more
blood relatives with melanoma (po0.001). No association was
apparent between development of melanoma in follow-up and
total nevus counts or dysplastic nevus counts. The patients
developing melanoma also did not differ significantly from the
remainder of the cohort in hair color, eye color, or tendency to
burn and tan. Annual melanoma incidence by personal and
family history of melanoma is presented in Table III. Ten of the 11
melanomas were excised because of change in a pre-existing
nevus. One melanoma developed de novo in follow-up. Five of
the changing lesions were appreciated by the patients to have
changed. The remaining five changed lesions and the de novo
melanoma were identified by the physician in comparison to
baseline photographs. Only two of the 11 lesions were clinically
diagnosed as melanoma at the time of excision. One of these two
Table I. Clinical Characteristics of 153 Study Subjects
Hair color Red Blond Light brown Brown/black
5 (3%) 36 (24%) 39 (25%) 71 (46%)
Eye color Blue Hazel Light brown Brown
62 (41%) 42 (27%) 7 (5%) 40 (26%)
Tendency to bum Severe Moderate Mild None
16 (10%) 67 (44%) 63 (41%) 7 (5%)
Ability to tan None Mild Moderate Deep
6 (4%) 64 (42%) 70 (46%) 13 (9%)
Freckling Severe Moderate Mild None
29 (19%) 48 (31%) 52 (34%) 23 (15%)
Figure 1. Total nevus count by dysplastic nevus (DN) count. (Data bars add
up to 100% for each total nevus count category.)
Figure 2. Dysplastic nevus (DN) count by age.
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lesions proved to be an in situ melanoma. A precursor dysplastic
nevus was found in histologic contiguity with seven of the excised
melanomas. A precursor dermal nevus was found on histologic
examination of one additional melanoma, and in three cases no
precursor nevus was appreciated on histologic evaluation.
DISCUSSION
As noted in Table II, the high rate of melanoma observed in the
entire study population (overall crude rate of 982 melanomas/
100,000 patient years of follow-up) is highly influenced by the
profound risk of melanoma associated with dysplastic nevi in the
context of familial melanoma. We chose to include the incident
melanomas in assigning familial melanoma status to maximize
sensitivity to hereditary melanoma. Our data corroborate the
earlier prospective observations of Greene et al in 14 melanoma-
prone kindreds [3]. They found an age-adjusted incidence for
melanoma of 1430/100,000 patient years among subjects with
dysplastic nevi in these kindreds. The formidable lifetime risk of
developing melanoma in these individuals and the relative
complexity of their cutaneous examinations warrant professional
intervention. It has been demonstrated that a regimen of self-
examination coupled with photographically assisted professional
surveillance leads to the discovery of biologically early melano-
mas in these patients [12,13]. The excellent prognostic attributes
of the incident melanomas in our cohort and the important role of
self-examination, photography, and follow-up in identifying these
early lesions further supports the efficacy of such a regimen in this
patient population.
The high incidence of melanoma noted here in patients with
dysplastic nevi and a personal history of melanoma is also in
keeping with prior observations. A personal history of melanoma
has been found to be an independent risk factor for the
development of malignant melanoma [14,15]. Furthermore,
among subjects with a personal history of melanoma, the
presence of dysplastic nevi has been shown to remain an
independent risk factor for the development of additional primary
cutaneous melanomas [16].
The most striking finding in our data set, as in the previous
observations of Rigel et al [17] and Tiersten et al [12], is the
dramatic incidence of melanoma in patients with dysplastic nevi
who lack both a personal and family history of melanoma.
Outside the context of familial melanoma, dysplastic nevi have
been shown to be an independent risk factor for melanoma in six
separate case-control studies. The point estimates of the adjusted
relative risks for dysplastic nevi in these six studies ranged from
2.1 to 7.7 and were statistically significant in all of the studies.
This significant but only moderately increased risk is less than that
observed in our patients (approximately 15 times the available
population-based estimates). This discrepancy may be in part
attributable to both our small sample size and the severity of our
patient’s dysplastic nevus phenotype. Our patients are a referred
or self-selected group of subjects and not a randomly ascertained
sample representative of people with dysplastic nevi in the
general population. Relatively high dysplastic nevus counts in our
patients and increased melanoma incidence are in keeping with
prior observations of a mild dose response of melanoma risk
Table II. Clinical Characteristics of Eleven Study Subjects with New Melanomas
Patient
Number
Age
(years)
Time to MMa
(months)
Thickness
(mm)
Categorical Total
Nevus Count
Categorical Dysplastic
Nevus Count
First-Degree
Relatives with MMa
Personal History
of Prior MMa
Precursorb
Nevus
1 44 29 In situ 50–100 6–10 Two Yes Dys
2 36 91 0.70 30–50 3–5 None No Dermal
3 43 110 0.52 30–50 1–2 One No None
4 47 64 0.34 50–100 10–20 None No Dys
5 48 11 0.63 50–100 420 None Yes Dys
6 51 143 0.68 50–100 10–20 None Yes Dys
7 35 35 0.32 50–100 420 One Yes Dys
8 51 40 0.42 30–50 3–5 None Yes None
9 45 60 0.85 4100 420 None Yes Dys
10 38 56 In situ 4100 420 None Yes Dys
11 47 23 0.25 50–100 1–2 One No None
aMM, malignant melanoma.
bDys, dysplastic.
Table III. Age-Adjusted Incidence Rates of Melanoma
in Follow-Up
Personal History
(MM/family status)a
Number
of
Incident
Melanomas
Follow-
Up
(person
years)
Crude
Incidence
Rateb
Age-
Adjusted
Incidence
Rateb,c
Negative (MM/not D-2) 2 678 295 154
Postive (MM/not D-2) 4 270 1,479 968
Negative (MM/D-2) 2 70 2,838 1,955
Positive (MM/D-2) 3 101 2,966 12,313
Entire Cohort 11 1,119 982 692
aMM, malignant melanoma; D-2, family history of two or more blood
relatives with melanoma inclusive of the patient’s personal history of
melanoma when applicable.
bIncidence rates are expressed per 100,000 person years.
cRates were standardized to the 1985 Pennsylvania population (whites)
using the direct method; 1985 Pennsylvania population (whites) overall
melanoma incidence 9.7/100,000 person years.
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associated with dysplastic nevi [5,6]. We, however, found no
association between melanoma incidence and counts of total
nevi or dysplastic nevi in this small study population. Addition-
ally, it is important to note that assignment of melanoma risk
should reflect the cumulative effect of multiple risk factors, as
noted by MacKie et al [5]. Indeed, many of our patients had
multiple risk factors for melanoma.
An important melanoma risk factor in many of our patients
was a high total nevus count. Dysplastic nevi are markers of
increased melanoma risk independent of total nevus counts;
however, there is a strong tendency to high total nevus counts in
patients with dysplastic nevi, as demonstrated in our patients (Fig 1).
Eighty-one (53%) of our study subjects had total nevus counts
greater than 50. Table I depicts the distribution of several other
melanoma risk factors among our patients. Striking is the
observation that 129 (84%) of our patients displayed some degree
of freckling, another independent risk factor in multiple case-
control studies [18–20]. Considering the following risk factors—
more than 50 nevi, blond or red hair, freckling, tendency to
severe sunburn, minimal or no ability to tan, and a history of
multiple painful or blistering sunburns—we found that 97% of our
patients with dysplastic nevi have at least one additional risk
factor, 82% have two or more, and 46% have three or more. The
identification of people with dysplastic nevi therefore translates
into the identification of people likely to possess multiple
independent risk factors for melanoma.
The previously documented importance of patient education
and professional surveillance in patients with dysplastic nevi [21]
is emphasized by our findings. Only two of the prospective
melanomas in this group were clinically diagnosed as melanoma
at the time of biopsy. Excision of lesions on the basis of observed
change rather than awaiting development of severe clinical atypia
resulted in the diagnosis of biologically early melanoma with an
associated excellent projected survival.
Melanoma incidence is rising at an alarming rate, with an
associated rise in melanoma mortality. Our most powerful weapon
against melanoma mortality is early recognition and surgical cure.
Recognition of early melanoma requires public education in skin
awareness and the warning signs of melanoma. The recognition of
dysplastic nevi permits focused efforts in patient education and
surveillance in a high-risk group. In the hereditary melanoma/
dysplas-tic nevus setting, the efficacy of intervention is evident.
Although the melanoma risk associated with dysplastic nevi in the
general population has been considered only moderately elevated,
we find that recognition of ‘‘sporadic’’ dysplastic nevi allows the
identification of people at significant risk. The elevated melanoma
risk in this identifiable segment of the population argues for targeted
education in cutaneous self-examination and, possibly, professional
follow-up. The subset of this high-risk population with skin
examinations complicated by large numbers of atypical nevi
benefits from photographically assisted professional follow-up in
addition to self-examination.
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